Theravance Biopharma, Inc. Appoints Deepika R. Pakianathan as Director
July 06, 2020 at 06:31 am EDT
Share
On July 1, 2020, Deepika R. Pakianathan was appointed by the Board of Directors of Theravance Biopharma, Inc. to serve as a Class III member of the Board of Directors. The Company’s Board of Directors has determined that Dr. Pakianathan is independent within the meaning of the independent director standards of the Securities and Exchange Commission and Nasdaq Stock Market, Inc. The Board of Directors has appointed Dr. Pakianathan to the Audit Committee and the Science and Technology Committee of the Board of Directors.
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath and others. Its pipeline of internally discovered programs is targeted to address unmet patient needs. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. Its Selective 5-HT4 Agonist (TD-8954) is a selective 5-HT4 receptor agonist, which is developed for the treatment of gastrointestinal motility disorders.
THERAVANCE BIOPHARMA, INC. 
